Chemical patent from PubChem database. Patent Number: AT-E400254-T1. Title: Pharmaceutical Formulation and Method of Use. Filing Date: 2013-01-26. Inventors: Wilson, James, Brown, Patricia, Lee, David. Abstract: The invention relates to pharmaceutical formulations containing active ingredients and methods for their therapeutic use in treating various medical c... IPC Classifications: B01J, C07C, C07D. This patent covers 45 claims related to 8 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.

The present invention generally relates to non-human transgenic animals expressing human cellular markers, including CD20 and/or preferably CD16.

Chemical patent from PubChem database. Patent Number: AT-E400277-T1. Title: Method for Synthesizing Organic Compounds. Filing Date: 1995-11-28. Inventors: Patel, Amit, Jones, Michael. Abstract: A method for synthesizing organic compounds is disclosed, comprising reacting starting materials under specific conditions to yield the desired produc... IPC Classifications: C07K, A61K, G01N. This patent covers 14 claims related to 8 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.

Recognition molecules (RM), especially antibodies (A) that bind specifically to the Core-1 (C1) antigen, comprising defined amino acids sequences (1-6) given in the specification and below, are new. Recognition molecules (RM), especially antibodies (A) that bind specifically to the Core-1 (C1) antigen, comprising defined amino acids sequences (1-6): (a) AsnTyrTrpLeuGly (1); (b) AspIleTyrPro(Gly) 3TyrThrAsnTyrAsnGluLysPheLysGly (2); (c) AspIleTyrPro(Gly) 2SerTyrThrAsnTyrAsnGluLysPheLysGly (3); (d) TyrAspAlaAlaGlyProTrpPheAlaTyr (4); (e) TyrAspAlaAlaGlyProGlyPheAlaTyr (5); or (f) TyrAspAsnHisTyrPheAspTyr (6). Independent claims are also included for: (1) construct (B) consisting of (A) fused, chemically coupled or non-covalently associated with additional sequences and/or structures; (2) isolated nucleic acid (NA) containing sequences that encode at least one (A) or (B); (3) expression cassette or vector (X) comprising NA and functionally linked promoter; (4) virus or host cell that contains at least one (X); (5) organism that contains at least one host cell of (4); (6) method for preparing (A); and (7) kit containing (A) and/or (B). ACTIVITY : Cytostatic. A multibody (104; sequence of about 200 amino acids reproduced) was coupled to a chelating group then loaded with yttrium99. It was injected (dose 100 MicroCi) into the tail vein of a mouse, subcutaneously implanted with ZA-75-1 (Core-1 positive) tumor cells. A second dose was given after 3 weeks and this treatment produced a significant reduction in tumor growth (no figures given). MECHANISM OF ACTION : Neutralization of Core-1 antigen; Vaccine.

Novel vectors are described that incorporate, inter alia, a novel 3' gene trap cassette which can be used to efficiently trap and identify previously unknown cellular genes. Vectors incorporating the described 3' gene trap cassette find particular application in gene discovery and in the production of mutated cells and animals.

The invention provides compositions for treating cancer in a mammal comprising an effective amount of a Newcastle Disease Virus. The invention also provides a composition for treating cancer in a mammal comprising a Newcastle Disease Virus in combination with another agent such as a chemotherapeutic compound, a cytokine, an immunosuppressive agent, or an antibody.

A method of preparing a transgenic animal model with enhanced, accelerated pathology for Alzheimer's Disease (AD) and the transgenic animal made by the method is disclosed. The method includes producing an F1 generation by crossing a first and second transgenic parent each carrying a different expressible transgene for differing aspects of the same desired phenotype associated with AD pathology. The offspring of the F1 generation are then screened and those which carry a transgene from each parental transgenic animal resulting in an enhanced pathology for Alzheimer's Disease are selected. In a preferred embodiment the AD-associated pathology is for amyloid accumulation. In an embodiment a mutant presenilin transgene and a transgene for a mutant amyloid precursor protein are used. In a further embodiment the mutant presenilin transgene is the PS1 M146L mutation and the mutant amyloid precursor protein transgene is the Swedish mutation (APP695 isoform containing a K670N,M671L mutation (APP770 numbering)).

Chemical patent from PubChem database. Patent Number: AT-E401096-T1. Title: Combinatorial Chemistry Method. Filing Date: 2006-06-26. Inventors: Kim, Young-Soo, Taylor, Elizabeth. Abstract: A combinatorial chemistry method for generating libraries of chemical compounds is disclosed, enabling rapid identification of lead compounds for drug... IPC Classifications: B01J, C07C, C07D. This patent covers 47 claims related to 4 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.

Chemical patent from PubChem database. Patent Number: AT-E401403-T1. Title: Novel Chemical Entity. Filing Date: 2010-12-13. Inventors: Martinez, Carlos, Thompson, Emily. Abstract: The invention relates to a novel chemical entity with unique structural features and biological properties, suitable for development as a therapeutic ... IPC Classifications: C12N, C12P, A61K. This patent covers 25 claims related to 9 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.

Selection (M1) of genotype variants from libraries in a micro-structure comprising feeding a test fluid (102) containing a genotype library in an expressible form and with suitable expression aids into a micro-structure together with a barrier fluid (101) to form separate compartments (109,111) in the test fluid, is new. An assay fluid (103) can be added to the test fluid compartments in (M1). The compartments are carried through the micro-structure to give an expression of the genotype in the phenotype in the compartments, for the phenotypes to be detected. The compartments are selected according to their detected phenotypes.